WallStSmart

Becton Dickinson and Company (BDX)vsEnvista Holdings Corp (NVST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Becton Dickinson and Company generates 706% more annual revenue ($21.92B vs $2.72B). BDX leads profitability with a 8.0% profit margin vs 1.7%. BDX trades at a lower P/E of 25.5x. BDX earns a higher WallStSmart Score of 61/100 (C+).

BDX

Buy

61

out of 100

Grade: C+

Growth: 5.3Profit: 5.5Value: 10.0Quality: 6.5
Piotroski: 6/9Altman Z: 1.49

NVST

Buy

56

out of 100

Grade: C

Growth: 7.3Profit: 4.5Value: 3.0Quality: 7.0
Piotroski: 5/9Altman Z: 1.47
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDXUndervalued (+36.9%)

Margin of Safety

+36.9%

Fair Value

$286.42

Current Price

$158.27

$128.15 discount

UndervaluedFair: $286.42Overvalued
NVSTSignificantly Overvalued (-131.0%)

Margin of Safety

-131.0%

Fair Value

$13.10

Current Price

$26.14

$13.04 premium

UndervaluedFair: $13.10Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDX3 strengths · Avg: 8.3/10
Market CapQuality
$56.49B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

EPS GrowthGrowth
28.6%8/10

Earnings expanding 28.6% YoY

NVST3 strengths · Avg: 8.7/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
15.0%8/10

15.0% revenue growth

EPS GrowthGrowth
31.5%8/10

Earnings expanding 31.5% YoY

Areas to Watch

BDX4 concerns · Avg: 3.3/10
P/E RatioValuation
25.5x4/10

Moderate valuation

Revenue GrowthGrowth
1.6%4/10

1.6% revenue growth

Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

Altman Z-ScoreHealth
1.492/10

Distress zone — elevated risk

NVST4 concerns · Avg: 2.5/10
Return on EquityProfitability
1.6%3/10

ROE of 1.6% — below average capital efficiency

Profit MarginProfitability
1.7%3/10

1.7% margin — thin

P/E RatioValuation
93.0x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.472/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BDX

The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.16 suggests the stock is reasonably priced for its growth.

Bull Case : NVST

The strongest argument for NVST centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 15.0% demonstrates continued momentum.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.

Bear Case : NVST

The primary concerns for NVST are Return on Equity, Profit Margin, P/E Ratio. A P/E of 93.0x leaves little room for execution misses. Thin 1.7% margins leave little buffer for downturns.

Key Dynamics to Monitor

NVST carries more volatility with a beta of 0.95 — expect wider price swings.

NVST is growing revenue faster at 15.0% — sustainability is the question.

BDX generates stronger free cash flow (549M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BDX scores higher overall (61/100 vs 56/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

Envista Holdings Corp

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Envista Holdings Corporation, develops, manufactures and markets dental products in the United States and internationally. The company is headquartered in Brea, California.

Visit Website →

Want to dig deeper into these stocks?